Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 185   

Articles published

GSK 1,652.46 +12.46 (0.76%)
price chart
Novartis to Buy Glaxo Cancer Drugs, Sell Animal Health
... total of as much as $28.5 billion today. The transactions, as well as a plan to form a consumer-health joint venture with Glaxo, are part of an overhaul of the pharmaceutical industry spurred by the loss of sales as best-selling medicines lose ...
Is This a Good Deal for Novartis AG and GlaxoSmithKline plc?  Motley Fool
GlaxoSmithKline plc's Dividends Set To Reach 5.4%!  The Motley Fool UK
Related articles »  
ADR Shares End Mixed; Novartis, Glaxo, Philips Shares Active
... (PHG, PHIA.AE). Drug giants Novartis and GlaxoSmithKline unveiled a series of transactions worth more than $20 billion that fundamentally transform both companies, focusing Novartis's scope without significantly hitting its revenue and turning ...
Glaxo, AstraZeneca lead UK stocks to two-week high  MarketWatch
U.K. Stocks Climb as M&A Activity Spur AstraZeneca, Glaxo  Bloomberg
Related articles »  
Is There Still Time To Buy GlaxoSmithKline plc?
Right now I'm looking at some of the most popular companies in the FTSE 100 and wider market to try and establish if there is still time for investors to buy in.
Glaxo: Results for heart-disease drug disappoint  MarketWatch
Glaxo Withdraws Application For Ovarian Cancer Treatment  Wall Street Journal
Related articles »  
Today's Health Care Stocks to Watch: Eli Lilly and Co, GlaxoSmithKline plc ...
In its deal with GlaxoSmithKline, Novartis purchased the company's high margin oncology unit for $14.5 billion, plus $1.8 billion in potential milestone payments, and subsequently sold its vaccine business to GlaxoSmithKline for $7.1 billion, plus ...
Novartis Buys Glaxo Cancer Unit, Sells Animal Drugs to Lilly
April 22 (Bloomberg) -- Novartis AG will focus more on cancer, GlaxoSmithKline Plc on vaccines and Eli Lilly & Co. on animal health as the drugmakers announced a series of deals for a total of as much as $28.5 billion today.
You Can't Go Far Wrong Buying GlaxoSmithKline plc At Today's Price
It has been some time since pharmaceutical giant GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) has been this cheap.
GlaxoSmithKline plc (ADR) (NYSE:GSK): A Drug To Tackle Bribery Scandals  BasicsMedia
Glaxo Disciplines Employee After Polish Bribery Charges  Bloomberg
Related articles »  
GlaxoSmithKline Plc (GSK) Is Up Sharply After Novartis Deal
GlaxoSmithKline plc (GSK: Quote) announced Tuesday morning that it agreed to sell its oncology products to Novartis (NVS: Quote) for US$14.5 billion payment and up to US$1.5 billion contingent on a development milestone.
Correction to Glaxo Exits Cancer Drugs
LONDON--GlaxoSmithKline PLC's (GSK) decision to leave the hot field of cancer drugs narrows the focus of its business to just four areas: respiratory and HIV treatments, vaccines and consumer-health products.
Novartis-Glaxo Unit Swaps Show Industry Overhaul  Businessweek
Can GlaxoSmithKline PLC Rule The World?  The Motley Fool UK
Related articles »  
GlaxoSmithKline plc Receives �Buy� Rating from Beaufort Securities (GSK)
GlaxoSmithKline plc (LON:GSK)'s stock had its �buy� rating reiterated by research analysts at Beaufort Securities in a report released on Wednesday, Analyst RN reports.
GlaxoSmithKline plc's "Neutral" Rating Reaffirmed at UBS AG (GSK)  Ticker Report
GlaxoSmithKline plc Upgraded to "Buy" at Argus (GSK)  Zolmax
Related articles »  
Should You Buy GlaxoSmithKline plc After Recent Declines?
I've been waiting for a good opportunity to buy into GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) for some time now. Luckily, recent declines have made Glaxo's shares look attractive on a valuation basis but there are some issues surrounding the company ...